What's Happening?
SciNeuro Pharmaceuticals has received a $5 million grant from The Michael J. Fox Foundation to accelerate the development of its novel LRRK2-targeted antisense oligonucleotide program, SNP614. This funding will support the preclinical development of SNP614,
which has shown potent efficacy and safety in non-human primate models. The initiative aims to advance the program toward clinical translation, potentially offering new treatment options for Parkinson's disease.
Why It's Important?
The funding from The Michael J. Fox Foundation underscores the significance of developing LRRK2-targeted therapies for Parkinson's disease, a condition with limited treatment options. SciNeuro's SNP614 program represents a promising therapeutic strategy that could bring significant benefits to patients. The collaboration with MJFF's LRRK2 Investigative Therapeutics Exchange program facilitates shared resources and expertise, accelerating the development of improved treatments for Parkinson's disease.
What's Next?
SciNeuro will continue to advance SNP614 toward an Investigational New Drug (IND) application, positioning the program for clinical trials. The collaboration with MJFF and other stakeholders in the LITE program will provide valuable resources and expertise to support the development of LRRK2-targeted therapies, potentially leading to breakthroughs in Parkinson's disease treatment.
